1-4 of 4
Zhengyi Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)

Zhijian Xiao, Chunkang Chang, Qiubai Li, Xiaojing Yan, Tiejun Qin, Hongyan Tong, Yu Zhang, Min Dai, Yanjie He, Jianyu Weng, Jian Li, Sujun Gao, Rong Fu, Xudong Wei, Aili He, Jinhai Ren, Tong Wu, Xin Du, Yanni Zhang, Ke Xu, Zhengyi Wang, Michelle Yang, Andrew Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 8821–8822.
https://doi.org/10.1182/blood-2022-163880
Published: 2022
Journal Articles

Exploration of the Therapeutic Effects of CD47 and CD38 Antibody Combination in Relapsed or Refractory Multiple Myeloma (rrMM) and the Correlation with CD47 and CD38 Expression

Yanni Zhang, Zhen Sheng, Jie Xia, Chunyan Ye, Yan Liu, Zhengyi Wang, John Hayslip, Andrew Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 9937–9938.
https://doi.org/10.1182/blood-2022-164755
Published: 2022
Journal Articles

Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results

Amitkumar Mehta, Wael Harb, Claire Xu, Yuan Meng, Linda Lee, Vivian Yuan, Zhengyi Wang, Pengfei Song, Joan Huaqiong Shen, Ajay K Gopal
Journal: Blood
Blood (2021) 138 (Supplement 1): 3542.
https://doi.org/10.1182/blood-2021-150606
Published: 2021
Journal Articles

TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties

Zhen Meng, PhD, Zhengyi Wang, PhD, Bingshi Guo, PhD, Wei Cao, PhD, Huaqiong Shen, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4063.
https://doi.org/10.1182/blood-2019-122793
Published: 2019